Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.04
- Piotroski Score 1.00
- Grade Buy
- Symbol (ARAY)
- Company Accuray Incorporated
- Price $1.83
- Changes Percentage (-0.82%)
- Change -$0.02
- Day Low $1.77
- Day High $1.87
- Year High $3.05
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/22/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.22
- Trailing P/E Ratio -8.09
- Forward P/E Ratio -8.09
- P/E Growth -8.09
- Net Income $-15,545,000
Income Statement
Quarterly
Annual
Latest News of ARAY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Osimhen scores 2 to help Galatasaray beat Tottenham 3-2 i the Europa League
Victor Osimhen led Galatasaray to a 3-2 win over Tottenham in the Europa League, scoring two goals within eight minutes. Galatasaray remains unbeaten while Tottenham suffered their first loss....
By AP NEWS | 1 week ago -
Victor Osimhen leads Galatasaray to action-packed victory as Spurs see red
Galatasaray and Tottenham played a thrilling match with numerous chances and goals, showcasing exciting attacking talent. Despite a spirited effort, Spurs fell short against Galatasaray, with standout...
By The Guardian | 1 week ago -
Galatasaray v Tottenham: Europa League - live
Gray is expected to play left-back for Spurs as Postecoglou tests his versatility. Galatasaray vs Tottenham lineups include key players like Icardi, Osimhen, and Son, showcasing a strong lineup for bo...
By The Guardian | 1 week ago
